Ocular Imaging
Safety Evaluation of Intravitreal Administration of rhuFab VEGF in Cynomolgus Monkeys for 3 Months
Invest Ophthalmol Vis Sci, 41 (4):S142 (2000).
Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105
Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4738-45. doi: 10.1167/iovs.09-4890. Epub 2010 Apr 14.
ABSTRACT
PURPOSE: To compare the relative contribution of VEGF and TNF-alpha in the development of laser-induced choroidal neovascularization (CNV) in monkeys and to exploit the feasibility of topical use of suitable antibody fragments for the prevention of experimental CNV.
Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates
Arch Ophthalmol. 2011 Aug;129(8):1042-52. doi: 10.1001/archophthalmol.2011.210.
ABSTRACT
OBJECTIVE: To evaluate the efficacy of systemic and intravitreous administration of VEGF Trap (aflibercept) in a nonhuman primate model of choroidal neovascularization (CNV).
Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin
Hum Gene Ther Clin Dev. 2015 Sep;26(3):165-76. doi: 10.1089/humc.2015.076.
ABSTRACT
Safety and Biodistribution Evaluation in CNGB3-Deficient Mice of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia
Hum Gene Ther Clin Dev. 2016 Mar;27(1):27-36. doi: 10.1089/humc.2015.163.
ABSTRACT
Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia
Hum Gene Ther Clin Dev. 2016 Mar;27(1):37-48. doi: 10.1089/humc.2015.164.
ABSTRACT
Single ocular injection of a sustained-release anti-VEGF delivers 6months pharmacokinetics and efficacy in a primate laser CNV model
J Control Release. 2016 Dec 28;244(Pt A):1-13. doi: 10.1016/j.jconrel.2016.10.026. Epub 2016 Nov 1.
ABSTRACT
Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics
J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):204-213. doi: 10.1089/jop.2017.0063. Epub 2017 Nov 17.
ABSTRACT
PURPOSE: The nonclinical toxicology program described here was designed to characterize the safety profile of anti-factor D (AFD; FCFD4514S, lampalizumab) to support intravitreal (ITV) administration in patients with geographic atrophy (GA).
Structure/function studies and the effects of memantine in monkeys with experimental glaucoma
Invest Ophthalmol Vis Sci. 2012 Apr 30;53(4):2368-76. doi: 10.1167/iovs.11-8475.
ABSTRACT